Avedro is developing non-surgical therapies for patients with vision impairment caused by ectatic corneal disorders like keratoconus. Their therapy aims to induce therapeutic remodeling of the cornea, allowing for improved vision correction with glasses or contact lenses, or halting disease progression.
Funding
Funding not disclosed
Founders
Product
Problem
Keratoconus and other ectatic corneal disorders cause vision impairment due to the gradual thinning and weakening of the cornea, resulting in an irregular, cone-like shape. Current treatments primarily address vision correction or halt disease progression, but do not offer a non-surgical method to restore the cornea's structural integrity. This leaves patients with limited options for long-term vision improvement.
Solution
TheiaNova is developing a non-surgical eyedrop therapy designed to induce therapeutic remodeling of the cornea for patients with keratoconus. The patented treatment combines human growth factor TGF-B3 and low-dose dexamethasone to regenerate collagen in the cornea. Applied twice daily over a three-week period, the eyedrops aim to rebuild the collagen matrix, restoring the cornea's structural integrity and rigidity. This approach offers a potential alternative to surgical interventions, improving vision and halting disease progression.
Target Audience
The primary target audience includes patients with keratoconus and other ectatic corneal disorders seeking non-surgical treatment options to improve vision and restore corneal health, as well as ophthalmologists and optometrists treating these conditions.
Features
- Patented eyedrop formulation combining TGF-B3 and low-dose dexamethasone
- Non-surgical treatment approach for corneal remodeling
- Designed to regenerate collagen in the cornea
- Aims to restore corneal structural integrity and rigidity
- Twice-daily application over a three-week period